NCT04555226Recruiting
The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)
Randomized Controlled Trial of the Efficacy of Lymph Node Dissection on Stage IIICr of Cervical Cancer
Source: ClinicalTrials.gov · Last updated 2 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is an national, prospective, multicenter and randomized clinical study designed to determine if patients with stage IIICr of cervical cancer have longer PFS and/or OS with lymph node dissection before CCRT when compared to CCRT.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 452 (estimated)
- First submitted
- 14 Sept 2020
- Start date
- 11 Jan 2021
- Primary completion date
- 31 Aug 2029
- Lead sponsor
- Chongqing University Cancer Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT04555226
What you commit to
- Study type: Interventional
- Planned participants: 452
- From 11 Jan 2021 to the primary completion date, 31 Aug 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has had an allogenic tissue/solid organ transplant
Other illness
- Activity or uncontrol severe infection
- Active hepatitis B, Liver cirrhosis, Decompensated liver disease
- History of immune deficiency, including HIV positive or suffering from other immunodeficiency disease
- Active autoimmune disease requiring systemic treatment (e.g., use of disease-modifying medications, corticosteroids, or immunosuppressive medications). Replacement therapies (e.g., thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency) were not counted as systemic therapies, and subjects were permitted to use these therapies
- Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
- Chronic renal insufficiency or renal failure
- Has combined with other malignant tumor which diagnosed within 5 years and/or needed to be treated
- Myocardial infarction, severe arrhythmia and NYHA (New York heart association)≥2 for congestive heart failure
- A history of pelvic artery embolization
- A history of pelvic radiotherapy
- A history of partial hysterectomy or radical hysterectomy
- A history of immunotherapy or undergoing immunotherapy
- A history of severe allergic reactions to platinum-based chemotherapy drugs, pembrolizumab and/or any excipients
- During the treatment for complications, the drugs which lead to serious liver and/or kidney function impairment need to be used, such as tuberculosis
Who the study is looking for
- Histopathology: squamous cell carcinoma, adenocarcinoma, adeno-squamous cell carcinoma
- Cervical cancer stage IIICr (confirmed by CT/MRI/PET/CT) and the short diameter of image-positive lymph node ≥15mm
- ECOG score 0\~1
- Expected survival over 6 months
- The serum or urine pregnancy test must be negative within 7 days before enrollment for the women of childbearing age who should agree that contraception must be used during the trial
- No surgical contraindication
Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chongqing Cancer Hospital Coordinator of this site? Confirm its status | Chongqing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.